Zaw Myint, MD
Hematology · Los Angeles, CANPI 1225243348
Payments from drug & device makers
Across 33 payments — averaging $17,763 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$385K
- Jazz Pharmaceuticals Inc.$89K
- E.r. Squibb & Sons, L.L.C.$40K
- Genentech, Inc.$37K
- Hoffmann-la Roche Limited$33K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- plus $391 from 9 others
What the payments were for
- Food & beverage$391100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 4 | $385,302 |
| Jazz Pharmaceuticals Inc. | 6 | $88,763 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40,325 |
| Genentech, Inc. | 3 | $36,955 |
| Hoffmann-la Roche Limited | 2 | $33,330 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,100 |
| Gilead | 4 | $134 |
| Sanofi | 3 | $67 |
| AbbVie | 2 | $42 |
| Astellas Pharma US Inc | 1 | $32 |
| Alnylam Pharmaceuticals Inc. | 1 | $30 |
| Ipsen Biopharmaceuticals, Inc | 1 | $25 |
| Sobi, Inc | 1 | $24 |
| Johnson & Johnson | 1 | $21 |
| Next Science LLC | 1 | $16 |
How this compares
$586,166 in reported general payments places this provider in the 65th percentile of 178 hematology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 18 | $480,875 |
| Lenalidomide | 16 | $273,905 |
| ZarxioFilgrastim-Sndz | 12 | $74,575 |
| Acyclovir | 81 | $823 |
| Ondansetron OdtOndansetron | 15 | $441 |
| Gabapentin | 15 | $182 |
| Allopurinol | 38 | $159 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $82 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 20 | $26 |
| Levofloxacin | 11 | $19 |
Paid to pharmacies, not to this prescriber.
Other hematology in Los Angeles
- Ilene WeitzLos Angeles$5.2M
- Doris QuonLos Angeles$2M
- Caroline PiatekLos Angeles$1.4M
- Tait ShanafeltStanford$441.4M
- Alex HerreraDuarte$50.9M
- Hope RugoSan Francisco$23.8M
- Tycel PhillipsDuarte$21.6M
- Lihua BuddeDuarte$21.5M
- Tanya SiddiqiDuarte$18.8M
- Amrita KrishnanDuarte$14M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.